Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present).
Zhihao GuYong YanHequan YaoKejiang LinXuanyi LiPublished in: Expert opinion on therapeutic patents (2022)
Over the past decade, a large number of antagonists targeting the LPA1 signaling pathway have been patented for fibrosis therapy. A limited number of compounds have entered clinical trials. Different companies and research groups have used different scaffolds when designing compounds for fibrosis therapy. Therefore, LPA1 and ROCK are competitive targets for the development of new therapies for fibrosis to provide a potential treatment method for fibrosis in the future.